RxDoctor Payments Data

Emily Schmaltz

Nurse Practitioner · Milan, INNPI 1710420609

Payments from drug & device makers

$952in general payments, 2019–2025

Across 69 payments — averaging $13.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$498
  • Novo Nordisk$125
  • Lilly USA, LLC$100
  • GSK$46
  • Abbott$44
  • Insulet Corporation$35
  • plus $104 from 6 others

What the payments were for

  • Food & beverage$952100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$952 in reported general payments places this provider in the 70th percentile of 2,724 nurse practitioner providers in Indiana.

See all nurse practitioner providers in Indiana

Medicare billing

Part B allowed, 2024
$44,608
Medicare patients
134
Services billed
789

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide82$108,237
EliquisApixaban88$86,251
Trelegy ElliptaFluticasone/Umeclidin/Vilanter77$62,246
JardianceEmpagliflozin37$57,079
JanuviaSitagliptin Phosphate31$44,358
TrulicityDulaglutide31$40,616
RybelsusSemaglutide14$26,386
MounjaroTirzepatide17$26,022
VraylarCariprazine Hcl14$19,926
XareltoRivaroxaban24$17,028
FarxigaDapagliflozin Propanediol12$11,292
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$10,186
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen201$4,769
Lantus SolostarInsulin Glargine,hum.Rec.Anlog26$3,454
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate18$3,270

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$125$134,62396 claims
Lilly USA, LLCTrulicity, Mounjaro$100$66,63848 claims
GSKTrelegy Ellipta$46$62,24677 claims
AbbVieVraylar$498$19,92614 claims
AstraZenecaFarxiga$15$11,29212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,724 nurse practitioner providers in Indiana.

Other nurse practitioner in Milan

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →